Back to search results
NCT00895271

Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

Enrolling by Invitation
Not specifiedAges 2–85Observational
National Institute of Allergy and Infectious Diseases (NIAID)
~200 participants
Updated 2026-07-17 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Generate fibroblast, dermal, or other skin-resident cell lines
Measured over Over the lifetime of the study

Conditions

Primary Immunodeficiency
DOCK8
Virus Susceptibility

Explore related trials

Common Variable ImmunodeficiencyHealthy VolunteerImmunodysregulationInborn Error of ImmunitySevere Combined Immunodeficiency

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Helen C Su, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Allergy and Infectious Diseases (NIAID)

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Generate fibroblast, dermal, or other skin-resident cell linesOver the lifetime of the study

    Obtain skin punch biopsies to generate fibroblast, dermal, or other skin-resident cell lines in patients who previously underwent HSCT. Cells may also be used for somatic cell hybridization, cell complementation, assessing fibroblast-specific innate immune responses, or other genetic techniques.